A Combination of Tanacetum parthenium, Griffonia simplicifolia and Magnesium (Aurastop) as Symptomatic Acute Treatment for Migraine Aura: A Retrospective Cohort Study
Background: effective
treatments for migraine aura and related symptoms are not yet well established.
In the last years, several herbal and/or nutraceutical preparations have been proposed as potential
treatment. We report the results of a retrospective analysis on the synergistic
effect of three nutraceutical components (Tanacetumparthenium, Griffonia simpliciofila and
Magnesium, Aurastop) as symptomatic treatment of migraine aura and related
symptoms. Method: Forty-nine subjects with headache with aura were recruited
from the headache Center of the Istituto Clinico
Citta’ di Brescia to enter the studied that consist
to treat the first 3 aura attacks as usual and the next 3 taking a tablet of Aurastop
at the beginning of the aura phenomena. They had to describe aura and headache
characteristics of previous three attacks (t1) and the modification of these
parameters with the assumption of Aurastop for the following three attacks
(t2). Results: A significant reduction (>50%) in aura duration (t1 = 33.6 ± 10.1 minutes vs. t2 = 9.4 ± 6.2 minutes, p < 0.01
FWER corrected) as well as in overall disability (median [interquartile range]) (t1 = 5[4 - 5] vs. t2 = 1[1 - 2], p < 0.01 FWER corrected) was evident. Furthermore,
modification of aura type as well as a series of parameters more related to
headache (number of headache attacks, duration, intensity, utilization of
analgesics and response to symptomatic treatment) was influenced by Aurastop utilization (p < 0.01 FWER corrected). No
significant adverse effects were recorded after the assumption of Aurastop. Conclusions:
the combined and synergistic effect of Tanacetumparthenium, Griffonia simpliciofila and
Magnesium (Aurastop) highlights the idea that symptomatic treatment
potentially modulating cortical spreading depression could deserve attention to
mitigate aura and related symptoms (migraine as well as long-lasting
discomfort). Further blinded, placebo-controlled studies on larger groups are
warranted.
Cite this paper
Zavarise, P. and Volta, G. D. (2017). A Combination of Tanacetum parthenium, Griffonia simplicifolia and Magnesium (Aurastop) as Symptomatic Acute Treatment for Migraine Aura: A Retrospective Cohort Study. Open Access Library Journal, 4, e3660. doi: http://dx.doi.org/10.4236/oalib.1103660.
Lipton, R.B.,
Bigal, M.E.,
Diamond, M.,
Freitag, F.,
Reed, M.L.
and
Stewart, W.F. (2007) Migraine
Prevalence, Disease Burden, and the Need for Preventive Therapy. Neurology, 68, 343-349. https://doi.org/10.1212/01.wnl.0000252808.97649.21
Bloudek, L.M., Stokes, M., Buse, D.C.,
Wilcox, T.K.,
Lipton, R.B.,
Goadsby, P.J., et al. (2012) Cost
of Healthcare for Patients with Migraine in Five European Countries: Results from
the International Burden of Migraine Study (IBMS). The Journal of Headache and Pain, 13, 361-378. https://doi.org/10.1007/s10194-012-0460-7
Steiner, T.J., Birbeck, G.L., Jensen, R.,
Katsarava, Z.,
Martelletti, P.
and
Stovner, L.J. (2011) The
Global Campaign, World Health Organization and Lifting the Burden: Collaboration in
Action. The Journal of Headache and Pain, 12, 273-274. https://doi.org/10.1007/s10194-011-0342-4
Russell, M.B., Rasmussen, B.K., Thorvaldsen, P.
and
Olesen, J.
(1995) Prevalence
and Sex-Ratio of the Subtypes of Migraine. International
Journal of Epidemiology, 24, 612-618. https://doi.org/10.1093/ije/24.3.612
Charles, A. and Hansen, J.M. (2015) Migraine
Aura: New Ideas about Cause, Classification, and Clinical Significance. Current Opinion in Neurology, 28, 255-260. https://doi.org/10.1097/WCO.0000000000000193
Petrusic, I. and Zidverc-Trajkovic, J.
(2014) Cortical
Spreading Depression: Origins and Paths as Inferred from the Sequence of Events
during Migraine Aura. Functional
Neurology, 29, 207-212.
Hadjikhani, N., Sanchez Del Rio, M., Wu, O.,
Schwartz, D.,
Bakker, D.,
Fischl, B., et al. (2001) Mechanisms
of Migraine Aura Revealed by Functional MRI in Human Visual Cortex. Proceedings of the National Academy of
Sciences of the United States of America, 98, 4687-4692. https://doi.org/10.1073/pnas.071582498
Thorlund, K., Mills, E.J., Wu, P.,
Ramos, E.,
Chatterjee, A.,
Druyts, E., et al. (2014) Comparative
Efficacy of Triptans for the Abortive Treatment of Migraine: A Multiple
Treatment Comparison Meta-Analysis. Cephalalgia: An International Journal of Headache, 34, 258-267. https://doi.org/10.1177/0333102413508661
Afridi, S.K., Giffin, N.J., Kaube, H.
and
Goadsby, P.J. (2013) A Randomized
Controlled Trial of Intranasal Ketamine in Migraine with Prolonged Aura. Neurology, 80, 642-647. https://doi.org/10.1212/WNL.0b013e3182824e66
Hauge, A.W., Asghar, M.S., Schytz, H.W.,
Christensen, K.
and
Olesen, J. (2009) Effects
of Tonabersat on Migraine with Aura: A Randomised, Double-Blind, Placebo-Controlled
Crossover Study. The Lancet Neurology,
8, 718-723. https://doi.org/10.1016/S1474-4422(09)70135-8
Rajapakse, T. and Pringsheim, T. (2016)
Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use. Headache, 56, 808-816. https://doi.org/10.1111/head.12789
Diener, H.C., Pfaffenrath, V., Schnitker, J.,
Friede, M.
and
Henneicke-von Zepelin, H.H. (2005)
Efficacy and Safety of 6.25 mg t.i.d. Feverfew CO2-Extract (MIG-99)
in Migraine Prevention—A Randomized, Double-Blind, Multicentre, Placebo-Con- trolled
Study. Cephalalgia: An International Journal of Headache, 25,
1031-1041.
Tassorelli, C.,
Greco, R.,
Morazzoni, P.,
Riva, A.,
Sandrini, G.
and
Nappi, G. (2005)
Parthenolide Is the Component of Tanacetum parthenium That Inhibits Nitroglycerin-Induced
Fos Activation: Studies in an Animal Model of Migraine. Cephalalgia: An International
Journal of Headache, 25, 612-621. https://doi.org/10.1111/j.1468-2982.2005.00915.x
Chauvel, V., Vamos, E., Pardutz, A.,
Vecsei, L.,
Schoenen, J.
and
Multon, S.
(2012) Effect
of Systemic Kynurenine on Cortical Spreading Depression and Its Modulation by
Sex Hormones in Rat. Experimental
Neurology, 236, 207-214. https://doi.org/10.1016/j.expneurol.2012.05.002
Sun-Edelstein, C. and Mauskop, A. (2009)
Role of Magnesium in the Pathogenesis and Treatment of Migraine. Expert Review of Neurotherapeutics, 9,
369-379. https://doi.org/10.1586/14737175.9.3.369
Farrar, J.T., Young Jr., J.P., LaMoreaux, L.,
Werth, J.L.
and
Poole, R.M. (2001)
Clinical Importance of Changes in Chronic Pain Intensity Measured on an
11-Point Numerical Pain Rating Scale. Pain,
94, 149-158. https://doi.org/10.1016/S0304-3959(01)00349-9
Viana, M., Linde, M., Sances, G.,
Ghiotto, N.,
Guaschino, E.,
Allena, M., et al. (2016)
Migraine Aura Symptoms: Duration, Succession and Temporal Relationship to
Headache. Cephalalgia: An International Journal of Headache, 36,
413-421. https://doi.org/10.1177/0333102415593089
Matei, D., Constantinescu, V., Corciova, C.,
Ignat, B.,
Matei, R.
and
Popescu, C.D. (2015) Autonomic
Impairment in Patients with Migraine. European
Review for Medical and Pharmacological Sciences, 19, 3922-3927.
Petrusic, I.,
Zidverc-Trajkovic, J., Podgorac, A.
and
Sternic, N. (2013)
Underestimated Phenomena: Higher Cortical Dysfunctions during Migraine Aura. Cephalalgia: An International Journal of Headache, 33, 861-867. https://doi.org/10.1177/0333102413476373
Hansen, J.M., Baca, S.M., Vanvalkenburgh, P.
and
Charles, A. (2013)
Distinctive Anatomical and Physiological Features of Migraine Aura Revealed by
18 Years of Recording. Brain, 136,
3589-3595. https://doi.org/10.1093/brain/awt309
Lampl, C., Katsarava, Z., Diener, H.C.
and
Limmroth, V. (2005)
Lamotrigine Reduces Migraine Aura and Migraine Attacks in Patients with
Migraine with Aura. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1730-1732. https://doi.org/10.1136/jnnp.2005.063750
Materazzi, S.,
Benemei, S., Fusi, C.,
Gualdani, R., De
Siena, G.,
Vastani, N., et al. (2013) Parthenolide
Inhibits Nociception and Neurogenic Vasodilatation in the Trigeminovascular
System by Targeting the TRPA1 Channel. Pain, 154, 2750-2758.
Ho, T.W.,
Ferrari, M.D.,
Dodick, D.W.,
Galet, V., Kost, J., Fan, X., et al. (2008) Efficacy
and Tolerability of MK-0974 (Telcagepant), a New Oral Antagonist of Calcitonin
Gene-Related Peptide Receptor, Compared with Zolmitriptan for Acute Migraine: A
Randomised, Placebo-Controlled, Parallel-Treatment Trial. The
Lancet, 372, 2115-2123. https://doi.org/10.1016/S0140-6736(08)61626-8
Curto, M.,
Lionetto, L.,
Negro, A., Capi, M.,
Fazio, F.,
Giamberardino, M.A., et al. (2015) Altered Kynurenine Pathway Metabolites in Serum
of Chronic Migraine Patients. The Journal
of Headache and Pain, 17, 47. https://doi.org/10.1186/s10194-016-0638-5
Mody, I., Lambert, J.D. and
Heinemann, U. (1987)
Low Extracellular Magnesium Induces Epileptiform Activity and Spreading
Depression in Rat Hippocampal Slices. Journal
of Neurophysiology, 57, 869-888.
Teigen, L. and Boes, C.J. (2015) An
Evidence-Based Review of Oral Magnesium Supplementation in the Preventive
Treatment of Migraine. Cephalalgia: An International Journal of Headache, 35,
912-922. https://doi.org/10.1177/0333102414564891
Begon, S., Pickering, G., Eschalier, A.,
Mazur, A.,
Rayssiguier, Y. and
Dubray, C. (2001)
Role of Spinal NMDA Receptors, Protein Kinase C and Nitric Oxide Synthase in
the Hyperalgesia Induced by Magnesium Deficiency in Rats. British Journal of Pharmacology, 134, 1227-1236.